

**Citation for published version:**

C. Christopoulos, M. Farag, K. Sullivan, D. Wellsted, and D. A. Gorog, 'Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention', *Thrombosis and Haemostasis*, Issue 3: 457-470, March 2017.

**DOI:**

<https://doi.org/10.1160/TH16-09-0712>

**Document Version:**

This is the Accepted Manuscript version.

The version in the University of Hertfordshire Research Archive may differ from the final published version.

**Copyright and Reuse:**

Published by Schattauer Publishers, Stuttgart.

Content in the UH Research Archive is made available for personal research, educational, and non-commercial purposes only. Unless otherwise stated, all content is protected by copyright, and in the absence of an open license, permissions for further re-use should be sought from the publisher, the author, or other copyright holder.

**Enquiries**

If you believe this document infringes copyright, please contact the Research & Scholarly Communications Team at [rsc@herts.ac.uk](mailto:rsc@herts.ac.uk)

## **Impaired Thrombolytic Status Predicts Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention**

Christos Christopoulos MB BCh <sup>1,2\*</sup>, Mohamed Farag MSc <sup>1,2\*</sup>, Keith Sullivan PhD <sup>1</sup>, David Wellsted PhD <sup>1</sup>, Diana A Gorog MB BS, MD, PhD, FRCP <sup>1,2,3</sup>

\*These authors contributed equally to this manuscript.

1. Postgraduate Medical School, University of Hertfordshire, UK
2. Department of Cardiology, East and North Hertfordshire NHS Trust, Hertfordshire, UK
3. National Heart & Lung Institute, Imperial College, London, UK

Correspondence to:

Prof. Diana A Gorog

Imperial College, London, UK

Tel +44 (0)207 034 8934

[d.gorog@imperial.ac.uk](mailto:d.gorog@imperial.ac.uk)

Total word count: 3815

## Summary

Antithrombotic medications reduce thrombosis but increase bleeding. Identification of ST-elevation myocardial infarction (STEMI) patients at risk of recurrent thrombosis could allow targeted treatment with potent antithrombotic medications, with less potent agents in others, to reduce bleeding. Conventional platelet function tests assess platelet reactivity only, yet there is increasing evidence that endogenous thrombolytic potential determines outcome following thrombus initiation. We investigated whether assessing both platelet reactivity and endogenous thrombolysis, could identify STEMI patients at high-risk of recurrent thrombotic events. Thrombotic status was assessed in STEMI patients, before and after primary percutaneous coronary intervention (PPCI), at discharge and at 30 days; with 12 months' follow-up. The time to form an occlusive thrombus under high shear (occlusion time, OT), and time to restore flow by endogenous thrombolysis (lysis time, LT) was measured using the point-of-care Global Thrombosis Test (GTT) in the cardiac catheterisation laboratory. Impaired endogenous thrombolysis (prolonged  $LT \geq 3000s$ ), seen in 13% patients pre-PPCI, was related to major adverse cardiac events, MACE (HR:3.31, 95%CI:1.02-10.78,  $p=0.045$ ), driven by cardiovascular death (HR:4.17, 95%CI:0.99-17.51,  $p=0.05$ ). Enhanced (rapid) endogenous thrombolysis ( $LT < 1000s$ ) was associated with spontaneous reperfusion, ST-segment resolution and Thrombolysis In Myocardial Infarction 3 flow pre-PPCI. Baseline OT was shorter in those with MACE (especially recurrent myocardial infarction and stroke) than those without ( $253 \pm 150s$  vs.  $354 \pm 134s$ ,  $p=0.017$ ). Endogenous thrombolysis, when impaired, is associated with increased cardiovascular risk, and when enhanced, with spontaneous reperfusion. Endogenous thrombolysis may be a novel target for pharmacological intervention, and allow targeting of potent antithrombotic medications to high-risk patients.

Word count 246

**Key words:** percutaneous coronary intervention, thrombosis, endogenous thrombolysis, myocardial infarction, coronary reperfusion

## **Abbreviations**

ACS = acute coronary syndrome

CVD = cardiovascular death

GPI = glycoprotein IIb/IIIa inhibitors

GTT = global thrombosis test

LT = lysis time

MACE = major adverse cardiovascular events

MI = myocardial infarction

NOACs = non-vitamin K antagonist oral anticoagulants

OT = occlusion time

PFTs = platelet function tests

PPCI = primary percutaneous coronary intervention

STEMI = ST-elevation myocardial infarction

## Introduction

Thrombotic occlusion of a coronary artery upon a background of atherosclerotic plaque rupture is considered the ultimate and key step in the pathogenesis of myocardial infarction (MI) (1). The emergency treatment of ST-elevation myocardial infarction (STEMI) is therefore two-pronged; namely, the pharmacological treatment and prevention of recurrent thrombosis (through antithrombotic and antiplatelet medications), and the mechanical relief of the atherosclerotic stenosis through primary percutaneous coronary intervention (PPCI). Even after mechanical relief of obstruction, there are many patients in whom there is failure to establish Thrombolysis in Myocardial Infarction (TIMI) 3 flow and a persistent pro-thrombotic state contributes to ongoing microvascular thrombosis and extension of infarction. Introduction of increasingly potent antithrombotic and antiplatelet agents has reduced the risk of recurrent thrombosis. Yet despite such treatment, some 10 to 15% of MI patients go on to have a major adverse cardiac event (MACE) after the index event, which is due predominantly to thrombotic complications (2-5). Contemporary, newer antithrombotic and antiplatelet agents, whilst reducing recurrent thrombosis, have significantly increased the risk of bleeding (5-8). Identification of individuals at high-risk of future thrombotic complications would be highly desirable, since this group could be targeted with more potent antithrombotic medications, allowing perhaps the use of less potent agents (thereby reducing bleeding risk) in lower risk groups.

Although many tests of platelet function tests (PFTs) are available, favourably modifying the results of PFTs through pharmacological modulation has not translated into a reduction in adverse thrombotic events. This may be due to intrinsic limitations of PFTs which differ from the *in vivo* situation (9), using citrated blood and measuring the response of platelets to only

specific agonists (10), which prevents assessment of thrombin generated by activated platelets or the effect of high shear (10), and importantly, spontaneous (endogenous) thrombolytic activity is not assessed. The innate ability of blood to induce lysis of a formed thrombus is an important defence mechanism against lasting arterial occlusion. Understandably, MI has been considered a result of the failure of timely spontaneous thrombolysis (11). The ideal test of thrombotic status should, in addition to assessing platelet reactivity, also measure the endogenous thrombolytic activity. Global assays, simultaneously assessing proaggregatory and fibrinolytic pathways, could play a role in risk stratification and in identifying impaired fibrinolysis as a potential target for pharmacological modulation (12).

The Global Thrombosis Test (GTT) (Thromboquest Ltd., London, UK), is a highly physiological, automated point-of-care test that assesses platelet reactivity, coagulation (thrombin generation) and endogenous thrombolysis from a native, non-anticoagulated blood sample. Impaired endogenous thrombolysis, as assessed by the GTT, has been shown to predict MACE in patients with non ST-elevation MI (13), and in patients with end-stage renal disease (14). As this test is performed from native (non-anticoagulated) blood, and assesses global thrombosis and thrombolysis, it is genuinely different from other PFTs which employ citrate-anticoagulated blood and cannot assess thrombolysis (10). We aimed to identify patients with STEMI undergoing PPCI who, despite dual antiplatelet medication, remain at risk of thrombotic complications and MACE, due to their inability to dissolve thrombus, namely impaired endogenous thrombolysis.

## Materials and Methods

### *Study design and population*

This prospective study was approved by the local research ethics committee. Consecutive eligible patients presenting with STEMI for emergency angiography with a view to PPCI, between the hours of 8 a.m. and 6 p.m. Monday-Friday, over the course of a year, were enrolled after obtaining informed consent. We included adults ( $\geq 18$  years) with a presumed diagnosis of STEMI based on clinical presentation and ECG criteria (namely: new ST-elevation at the J point in at least 2 contiguous leads of  $\geq 2$  mm (0.2 mV) in men or  $\geq 1.5$  mm (0.15 mV) in women in leads V2–V3 and/or of  $\geq 1$  mm (0.1 mV) in other contiguous chest leads or the limb leads, or ST-depression in  $\geq 2$  precordial leads (V1–V4), or new or presumably new left bundle branch block (LBBB) in patients with clinical suspicion of ongoing myocardial ischaemia (15, 16)). All patients had received a loading dose of aspirin 300mg and clopidogrel 600mg in the ambulance or in the emergency department upon diagnosis of STEMI, within the preceding 20-60 min, in line with current local standard of care. The exclusion criteria listed in Table 1 were applied. Clinical characteristics of patients are shown in Tables 2 and 3. [Unfractionated heparin \(UFH\) was given at a dose of 70 to 100 units per kilogram immediately before PPCI.](#) Use of the glycoprotein IIb/IIIa inhibitor (GPI) abciximab (Reopro, Eli Lilly, Indianapolis, Indiana, USA) or bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ, USA) was allowed at the operator's discretion, in conjunction with UFH. Decisions regarding access site, thrombus aspiration, and stent type were left to physician preference. Procedural characteristics are shown in Table 4. All patients received dual antiplatelet medication for 12 months as part of local protocol.



### ***Blood sampling***

Blood samples for thrombotic status were taken from all consented patients at 4 time points: 1) baseline upon admission (after loading with dual antiplatelet therapy, DAPT), through the arterial sheath, prior to heparin or GPI administration and before PPCI, 2) approximately 30-60 min after the administration of abciximab (if used), 3) at clinical stabilisation, just prior to hospital discharge, and 4) at 30 days' follow-up. Fasting was not required.

The first 2 time-point blood samples were taken from a 6-F radial or femoral sheath using a 2-syringe technique. For the initial sample, the sheaths were only ever flushed with normal saline (and not heparinised saline) prior to sampling. The third and fourth samples were taken from an antecubital vein using an 18-G butterfly cannula also using a 2-syringe technique, taking care to avoid prolonged tourniquet time. The two syringe technique involved using the first 5 ml blood for routine blood tests and using the second 5 ml for assessment of thrombotic status.

### ***Assessment of global thrombotic status***

The Global Thrombosis Test (GTT) (Thromboquest Ltd., London, UK), an automated point-of-care test, was used to assess both platelet reactivity and endogenous thrombolysis from a native, non-anticoagulated blood sample. The instrument has 4 independent measuring channels, and was positioned in the cardiac catheterisation laboratory. After blood sample was obtained, it was introduced into the disposable GTT cartridge, within 15 seconds of withdrawal and the automated measurement begun. The instrument assesses the time taken to form an occlusive thrombus under high shear stress (occlusion time, OT), and the time required to restore flow through endogenous thrombolysis (lysis time, LT). The principle of the GTT has previously been described in detail (13, 17). In brief, blood flows under high shear

conditions through narrow gaps inside the conical tube where thrombus formation occurs and the instrument measures the time (d) between 2 consecutive blood drops downstream of this. This time interval increases gradually as flow slows down and at an arbitrary point (d  $\geq$ 15s, before reaching complete occlusion), the end point of the measurement is displayed (occlusion time [OT], in seconds). Restart of blood flow after occlusion is due to spontaneous thrombolysis (lysis time [LT], in seconds). If lysis does not occur until >6,000s (LT cut-off time), “no lysis” is displayed and recorded. The coefficient of variation (cv) was assessed by testing a cohort of 10 stable patients on 2 occasions, 48 hours apart.

### ***ECG and Angiographic Analyses***

ECG and angiographic analyses were performed by two investigators blinded to clinical characteristics and outcome. Standard 12-lead ECGs were obtained on arrival in the cath lab and compared to that at baseline presentation (in ambulance or emergency department). All ECGs were analyzed using a hand-held caliper. The ST-segment was measured 20 ms after the J point, and the sum of ST deviation was measured as previously described (18). The percent resolution of ST deviation from baseline to arrival was calculated, and categorized using Schröder’s 3-component definition: complete ( $\geq$ 70%), partial (30% to 70%) and no ( $\leq$ 30%) ST resolution (18). Flow in the infarct-related artery was reported using the TIMI flow grading system and patency defined as TIMI grade 2 or 3 flow.

### ***Data collection and follow-up***

Patients were recruited during their index admission and their case notes and electronic records were examined, to allow contemporaneous completion of study-specific case record

forms. Patients were followed up at 30 days in person, and at 6 months and 1 year by telephonic follow up, for the occurrence of MACE, defined as the composite of cardiovascular death (CVD), nonfatal MI or stroke. The secondary endpoint was major bleeding. For all endpoints, source documents were obtained and diagnosis verified by 2 independent clinicians blinded to the GTT results. The end points of the study were as follows: CVD, recurrent non-fatal MI, stroke, and major bleeding, classified as type 3-5 according to the Bleeding Academic Research Consortium (BARC) definition (19). For definitions of endpoint events, please see Supplement 1.

### ***Statistical analysis***

A clinical trial assessing whether LT is a predictor of MACE in STEMI, based on an effect size (HR) of 2.5 (13), assuming a MACE rate of 10% and an attrition rate of 10% over the follow-up period, would require about 500 patients to achieve 80% power. Based on previous published guidance (20), a pilot study sample should include at least 10% of the sample projected for the larger study. We opted for 17% (85 patients) to allow for suitable numbers for the analysis.

Paired and unpaired t tests were used for comparison of normally distributed and Mann-Whitney U test used for non-normally distributed variables. Where necessary, log transformations were employed. Dichotomous variables were compared using chi-square test with continuity correction or Fisher's exact test, as appropriate. Correlations were analysed using Spearman's rank test. The OT and LT at baseline were related to the OT and LT at other time points. The OT and LT at the 4 time points were separately related to study end points of MACE or major bleeding. Separate analysis was used to compare the OT and LT of patients who had spontaneous coronary reperfusion to those who did not. Simple regression was used to examine the relationship between baseline OT and LT and pain to balloon time.

Ability of the test to discriminate between patients with and without MACE was evaluated by receiver-operating characteristic (ROC) curve analysis. Kaplan-Meier survival methods with log-rank tests were used. In addition, to investigate the relationship between increasing LT and MACE, univariate Cox proportional hazard regression was performed on LT. Univariate and multivariate hazard regression models of Cox were used, respectively, to identify risk factors for clinical end points and to adjust for potential confounders that were associated with clinical end points on univariate analysis. Net reclassification improvement (NRI) was used to assess the added predictive ability of  $LT \geq 3,000$  for MACE. Tests were two-sided, and significance was fixed at 0.05 level. Analyses were performed with Stata V.11.2 (StataCorp, College Station, Texas, USA).

## Results

Out of 85 eligible patients, 2 patients met one or more exclusion criteria, and 1 patient declined consent. The clinical characteristics are shown in Tables 2 and 3. Angiographic, procedural and echocardiographic characteristics are shown in Table 4. The coefficient of variation (cv) was 8% for OT and 10% for LT. [There was no relationship between baseline OT \( \$r=0.03\$ ,  \$p=0.592\$ \) or baseline LT \( \$r=0.71\$ ,  \$p=0.283\$ \) and the time of blood sampling.](#)

### ***Distribution and change in occlusion time***

Baseline OT was normally distributed and OT at the 4 sampling time points is shown in Figure 1. OT was markedly prolonged after GPI/UFH treatment (mean $\pm$ SD;  $743\pm 157s$  vs.  $330\pm 136s$ ,  $p=0.00001$ ) and after bivalirudin/UFH ( $707\pm 121s$  vs.  $381\pm 97s$ ,  $p=0.0004$ ) compared to baseline, and remained prolonged at hospital discharge ( $536\pm 195s$  vs.  $330\pm 136s$ ,  $p=0.00001$ )

and at 30 days ( $515\pm 147$ s vs.  $330\pm 136$ s,  $p=0.00001$ ) compared to baseline. OT was similar at hospital discharge and at 30 days' follow-up ( $536\pm 195$ s vs.  $515\pm 147$ s,  $p=0.695$ ).

### ***Distribution and change in lysis time***

The distribution of LT at the 4 time points is shown in Figure 2. Baseline LT was positively skewed and many patients exhibited impaired endogenous thrombolysis with prolonged lysis times. LT was significantly reduced after GPI/UFH compared to baseline (median[IQR] 747 [579-950] s vs. 1075 [882-1682] s,  $p=0.00001$ ). LT was similar at hospital discharge (1172 [931-2202] s vs. 1075 [882-1682] s,  $p=0.321$ ), and at 30 days' follow-up (1059 [806-1569] s vs. 1075 [882-1682] s,  $p=0.801$ ) compared to baseline [Figure 3-B]. At 30 days, LT was similar to LT at hospital discharge (1059 [806-1569] s vs. 1172 [931-2202] s,  $p=0.112$ ).

### ***Recurrent adverse clinical events and OT and LT***

There were a total of 13 MACE events experienced by 13 patients, namely 8 CVD, 3 nonfatal MI (of which 1 attributable to acute stent thrombosis within 24 hours and 1 attributable to late stent thrombosis at 76 days), and 2 ischaemic strokes (not associated with atrial fibrillation). There were a total of 2 major bleeding events (BARC type 3a). There were no reported non-compliance issues with antiplatelet medication in those patients who experienced an adverse event.

Patients who went on to experience a MACE event, demonstrated a baseline OT that was significantly shorter (more thrombotic) than the OT of patients who did not experience an adverse event ( $253\pm 150$ s vs.  $354\pm 134$ s;  $p=0.017$ ), particularly with respect to nonfatal MI (OT  $135\pm 45$ s vs.  $346\pm 137$ s;  $p=0.009$ ), and ischaemic stroke (OT  $133\pm 31$ s vs.  $343\pm 138$ s;  $p=0.036$ ) [Figure 4]. Baseline OT did not differ between patients who experienced a major bleed and those who did not ( $297\pm 121$ s vs.  $339\pm 141$ s;  $p=0.682$ ), but the number of events was small.

ROC curve analysis showed that no particular threshold of baseline OT was a good binary discriminator of MACE risk [Figure 5-A]. Survival analysis demonstrated no relationship between baseline OT and MACE (hazard ratio [HR]: 0.99, 95%CI:0.989-0.999) or major bleeding. At other pre-specified time points, OT was not related to MACE or major bleeding. Baseline LT level significantly discriminated between patients with and without MACE, with an area under the ROC curve of 0.59 (95% confidence interval [CI]:0.471-0.693;  $p < 0.05$ ) [Figure 5-B].  $LT \geq 2901s$  was the optimal cut-point to predict MACE (rounded to 3000s for clinical ease), with sensitivity 31% and specificity 89% [Figure 5-B]. There were no LT readings between 2900s and 3000s that could have been wrongly classified based on rounding the cut-point to 3000s. Survival analysis demonstrated that  $LT \geq 3000s$  at baseline was strongly related to MACE (HR:3.31, 95%CI:1.02-10.78,  $p = 0.045$ ) [Figure 6], driven by CVD (HR:4.17, 95%CI:0.99-17.51,  $p = 0.05$ ) [Figure 7-B and Table 5].  $LT \geq 3000s$  at baseline was not related to an increase in major bleeding, but the number of events was small. LT at the other pre-specified time points was not related to MACE or major bleeding.

### ***Spontaneous coronary reperfusion and ST-resolution***

Five STEMI patients had spontaneous coronary reperfusion, defined as complete or partial resolution of ST-elevation and chest pain before PPCI. All five patients had short baseline LT (<1000s), TIMI-3 flow at presentation, and uneventful 12-month outcomes. Lysis time was inversely correlated with spontaneous coronary reperfusion before PPCI ( $r = -0.3$ ,  $p = 0.022$ ). The baseline OT in those with spontaneous coronary perfusion was no different to those patients without spontaneous coronary reperfusion ( $306 \pm 156s$  vs.  $340 \pm 140s$ ,  $p = 0.609$ ).

### ***Influence of patient characteristics on OT and LT and outcomes***

There was a weak positive correlation between baseline OT and the time from symptom onset ( $r=0.2$ ,  $p=0.04$ ) but no relationship between baseline LT and time from symptom onset. The following variables were interrogated (using parametric or non-parametric tests, as appropriate) for effects on baseline OT and LT: all patient characteristics in Table 2; haematological and biochemical profiles on admission in Table 3; the echocardiographic, angiographic, and interventional characteristics in Table 4. Smokers exhibited a shorter (more thrombotic) OT than non-smokers ( $294\pm 105s$  vs.  $365\pm 153s$ ,  $p=0.026$ ). There was a weak negative correlation between baseline OT and creatinine level on admission ( $r= -0.4$ ,  $p=0.057$ ), and a weak positive correlation between baseline OT and pre-PCI TIMI-3 flow ( $r=0.2$ ,  $p=0.063$ ). None of the other variables including haematocrit, platelet count, troponin I, or left ventricular function correlated with baseline OT or LT. Female sex and patients with raised creatinine level on admission had significantly more baseline  $LT\geq 3000s$  values measured [Table 2 and Table 3]. Of the characteristics in Tables 2 and 3, only the following were related to MACE: increasing age ( $p=0.008$ ), statin therapy ( $p=0.012$ ), prior aspirin use ( $p=0.001$ ), beta-blocker treatment ( $p=0.024$ ), angiotensin-converting enzyme (ACE) inhibitor treatment ( $p=0.0008$ ), calcium antagonists ( $p=0.001$ ), prior renal insufficiency ( $p=0.002$ ), high serum creatinine ( $p=0.001$ ), and right coronary artery culprit vessel ( $p=0.020$ ). None of the variables were related to major bleeding outcome, but the number of events was small.

The following variables were then entered into the final baseline multivariate Cox proportional hazard model: age (HR:1.07, 95%CI:1.02-1.13,  $p=0.005$ ), statin therapy (HR:6.39, 95%CI:1.95-20.99,  $p=0.002$ ), and two traditional risk factors, namely diabetes (HR:0.51, 95%CI:0.15-1.71,  $p=0.276$ ) and hypertension (HR:0.51, 95%CI:0.16-1.60,  $p=0.246$ ). None of these basic covariates were correlated either with LT or its dichotomized version, such as sex, which would have increased the standard error of the HR in the Cox proportional hazard

model. We did not include prior aspirin use in the model, as although in our small sample it was not related to OT or LT, we felt biologically it was likely to have influenced baseline platelet reactivity and thus not a truly independent variable. Multivariate analysis including the baseline covariates showed that baseline  $LT \geq 3000s$  remained strongly related to MACE after adjustment for risk factors (HR:4.26, 95%CI:1.13-16.01,  $p=0.032$ ). Net reclassification improvement (NRI) showed that the inclusion of baseline  $LT \geq 3000s$  in a model containing three baseline predictors (age, statin therapy and diabetes) significantly added to the model effectiveness (NRI estimate 0.347,  $p=0.018$ ).



## Discussion

Impaired (prolonged) endogenous thrombolysis, seen in 13% STEMI patients at presentation, prior to PPCI, was predictive of an increased risk of adverse cardiovascular events, in particular cardiovascular death. Enhanced (rapid) endogenous thrombolysis was seen in patients with STEMI who demonstrated spontaneous coronary reperfusion, with spontaneous ST-segment resolution and TIMI-3 flow prior to intervention. Enhanced platelet reactivity, as demonstrated by short OT, was seen in patients with recurrent adverse events of nonfatal MI and stroke. Whilst the treatment with DAPT and PPCI, and the patient journey over time, resulted in OT prolongation; LT was similar pre-PPCI, at 30 days' follow-up and at hospital discharge. This would suggest that LT could be tested at any point up to 30 days, provided GPI is not used, and would not need to necessarily be tested prior to PPCI. However, although overall LT was similar at these time-points, only LT pre-PPCI was predictive of adverse cardiovascular events. This may at least in part be explained by the fact that many events occurred in the first 30 days [Figure 6] and that the "tail" of LT distribution, where some patients exhibited  $LT > 6000s$ , was no longer apparent at 30 days. [The AUC although significant, is overall small and while LT as a predictor of MACE is highly specific, its sensitivity is low, such that LT on its own is not a very good independent predictor of events. This may be better assessed in a larger study with a broad spectrum of patients which would avoid bias and allow for control of confounders, as well as allow calculation of the additive value of LT to other predictive markers in the assessment of LT performance as an additional predictive test.](#)

It would seem that antiplatelet medications favourably alter (prolong) OT to reduce platelet reactivity over time, but LT is unaffected by standard chronic pharmacological treatment and

coronary intervention. However, in the acute phase, administration of GPI results in marked prolongation of OT and reduction in LT, an effect that wears off by the time the patient leaves the hospital, when LT has returned to baseline.

Prior work has shown that aspirin at low doses does not alter LT. More potent antiplatelet agents such as clopidogrel have negligible effects on LT (21). In patients with atrial fibrillation, the administration of non-vitamin K antagonist oral anticoagulants (NOACs), but not warfarin, favourably modulates (reduces) LT (22, 23). Previously in a study of patients with coronary disease, treatment with the PAR1 inhibitor vorapaxar resulted in reduction of LT (24). Our current work lends further support to the notion that agents that inhibit thrombin, but not antiplatelet agents, can exert a favourable effect on endogenous thrombolysis. This may underlie the observed findings of adding NOACs on top of standard dual antiplatelet in patients with ACS, where in APPRAISE-2, RE-DEEM, and ATLAS ACS 2–TIMI 51 trials, a reduction in recurrent ischaemic events was observed when a NOAC was used (25-27).

Our data are supported by prior studies which have demonstrated that impaired endogenous thrombolysis is a risk factor for adverse cardiac events in a number of patient cohorts, including non-ST-elevation MI (13), end-stage renal failure (14), stroke (28) and diabetes (29). The cut-point of LT that predicts MACE appears to be consistent in our study and prior studies (13, 14). Furthermore, D-dimer levels on admission were associated with a higher incidence of no reflow (30) and higher risk of MACE in STEMI patients undergoing PPCI (31) and elevated levels post-PPCI were related to impairment of myocardial function (32). Furthermore, when intracoronary thrombi aspirated during PPCI were examined, increased von Willebrand factor, P-selectin and fibrin content were related to unfavourable thrombus characteristics rendering the thrombus resistant to lytic therapy (33) and denser plasma fibrin clots were independently associated with high fibrin content (34). Recently, a crucial role of fibrinolysis

in determining infarct outcome was shown by combined inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1, prior to transient cerebral artery occlusion in mice, which reduced cerebral infarct size by 50% (35).

Baseline  $LT \geq 3000s$  was more commonly seen in females in our study, and data show that women with STEMI tend to have a higher mortality than men, despite PPCI, and this is likely to be at least in part attributable to a worse risk profile (36-38). An earlier report assessing global thrombotic status showed no difference in LT between male and female healthy volunteers (39), thus whether the excess risk in women with STEMI may in part be related to worse thrombolytic status in the setting of STEMI, requires further study.

Others have shown that high residual platelet reactivity (HRPR) on DAPT as assessed with the VerifyNow technique was predictive of recurrent events, especially in ACS patients undergoing PCI (40, 41). However, those tests were uniformly performed on therapeutic DAPT, whereas our initial sample was performed before therapeutic levels of DAPT had been achieved, and our third sample was done at follow up, when almost all events had occurred. It would have been the pre-discharge sample that we would have expected to correlate with MACE. The discrepancy between earlier findings of HRPR and our results can be explained by the different techniques used. ADP-induced platelet aggregation (VerifyNow) is more sensitive than the GTT in detecting ADP antagonist effect. ADP-induced platelet aggregation measurement is based on the concept that ADP plays a crucial role in platelet aggregation and thrombus formation. The GTT measures thrombus formation at high shear stress. However, there is strong evidence that platelet aggregation induced by high shear (relevant to arterial shear rates *in vivo*) occurs independently of ADP (42, 43), which explains the lower sensitivity of GTT technique to ADP antagonism. The fact that ADP

mediated thrombus formation does not underlie all arterial thrombotic events also helps explain the low specificity (53%) reported with the Verify Now technique (44) and may support the validity of our results. The lower specificity of HRPR as measured by VerifyNow compared with LT measurement is further supported by emerging evidence showing the important role of P2Y<sub>12</sub> receptor signalling not in the growth rate but in the stability of the evolving thrombus. This effect can be measured by detecting disaggregation of ADP-induced aggregates and low disaggregation identified patients on clopidogrel at risk of MI with equal or better specificity than did the VerifyNow (45). The concept that alteration of thrombus stability plays a major role in the mechanism of the antithrombotic effect of antiplatelet medication is gaining momentum (46).

The main limitation of our study is the small sample size. As such, this data is hypothesis generating and requires validation in suitably powered, large, prospective clinical study. In addition, because of the need to consent patients pre-procedure, we excluded those who were *in extremis*, such as those with cardiogenic shock or out-of-hospital cardiac arrest, who were at very high risk of MACE and who may have had even worse thrombotic profile than the patients studied. Another limitation is that optimal antithrombotic medication in the context of STEMI comprises of aspirin combined with newer P2Y<sub>12</sub> inhibitors, namely ticagrelor or prasugrel. Whilst these medications are increasingly used, in much of the UK and elsewhere, clopidogrel and aspirin administration in the ambulance remains the “standard of care” due to financial constraints. It is unlikely that prasugrel or ticagrelor administration would have impacted on endogenous thrombolysis, but assessment of the effect of these newer and more potent antiplatelet medications would have been desirable. The study could not assess the relationship between thrombotic status and bleeding events,

since the number of bleeds was very small, probably helped by the majority (>90%) of interventions being performed radially. Furthermore, the timing of the first (baseline) sample was such that absorption of antiplatelet agents was unreliable and therapeutic doses were likely not have been reached. Although this may be a criticism of our study, it also reflects real-time thrombotic status at the time of PPCI.

For the first time, we show that impaired endogenous thrombolysis in STEMI patients is predictive of a high risk of adverse events despite good angiographic outcome, whilst patients with spontaneous coronary reperfusion and ST-segment resolution demonstrate enhanced (short) endogenous thrombolysis. Large clinical studies are needed to see if the addition of potent antithrombotic medications such as NOACs to standard care with DAPT in those with impaired endogenous thrombolysis, can reduce adverse events. The GTT may serve as a risk stratification tool to identify patients with impaired endogenous thrombolysis, and to target those who are most pro-thrombotic with selective escalation of antithrombotic medication, whether to further target platelets or thrombin; and to avoid excessive unnecessary antithrombotic agents in those who are at low risk.

## **What is known on this topic**

- The outcome of a thrombotic event depends on the balance between prothrombotic drivers and the effectiveness of the intrinsic endogenous thrombolytic potential.
- Contemporary antithrombotic and antiplatelet agents, whilst reducing recurrent thrombosis, have significantly increased the risk of bleeding.
- Identification of patients at high-risk of future thrombotic complications would be highly desirable, since this group could be targeted with more potent antithrombotic medications, allowing use of less potent agents (thereby reducing bleeding risk) in lower risk groups.

## **What this paper adds**

- in patients with STEMI presenting for PPCI, impaired endogenous thrombolysis, as measured in the catheterisation laboratory with the point-of-care Global Thrombolysis Test, is predictive of recurrent adverse.
- Patients with STEMI who demonstrate spontaneous reperfusion and spontaneous ST-segment resolution have enhanced (rapid) endogenous thrombolysis.
- Endogenous thrombolysis may be a novel target for pharmacological intervention in STEMI, and allow targeting of potent antithrombotic medications to high-risk patients.

## **Funding**

This study was funded by the East and North Hertfordshire NHS Trust.

## **Conflict of interest**

DAG is related through family to a company director of Thromboquest Ltd., which manufactures the Global Thrombosis Test, but she, her spouse, and her children have no financial involvement or equity interest in, and have received no financial assistance, support, or grants from Thromboquest Ltd. Thromboquest Ltd. has no involvement in the design, conduct, or the finance of this review. The other authors have reported no relationships relevant to the contents of this paper to disclose.

## References

1. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation*. 2003;108(15):1772-8.
2. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med*. 2011;365(21):1980-9.
3. Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macri M, Dicuonzo G, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). *Am J Cardiol*. 2012;110(4):478-84.
4. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. *N Engl J Med*. 2013;369(23):2207-17.
5. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. *Lancet*. 2014;384(9957):1849-58.
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357(20):2001-15.
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361(11):1045-57.
8. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med*. 2012;367(14):1297-309.
9. Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? *Nat Rev Cardiol*. 2009;6(5):365-73.
10. Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. *J Am Coll Cardiol*. 2013;61(21):2115-29.
11. Swan HJ. Acute myocardial infarction: a failure of timely, spontaneous thrombolysis. *J Am Coll Cardiol*. 1989;13(6):1435-7.
12. Okafor O, Gorog D. Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk. *J Am Coll Cardiol*. 2015;65:1683-99.
13. Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. *J Am Coll Cardiol*. 2010;55(19):2107-15.
14. Sharma S, Farrington K, Kozarski R, Christopoulos C, Niespialowska-Steuden M, Moffat D, et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. *Eur Heart J*. 2013;34(5):354-63.
15. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33(20):2569-619.
16. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;61(4):e78-140.
17. Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, et al. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. *Blood Coagul Fibrinolysis*. 2003;14(1):31-9.



18. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. *Am J Cardiol.* 2000;85(3):299-304.
19. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation.* 2011;123(23):2736-47.
20. Connelly LM. Pilot studies. *Medsurg Nurs.* 2008;17(6):411-2.
21. Saraf S, Wellsted D, Sharma S, Gorog DA. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. *Thromb Res.* 2009;124(4):447-51.
22. Niespialowska-Steuden M, Okafor O, Collins P, Srinivasan M, Gorog D. NOAC but not VKA Favorably affect endogenous thrombolytic status: a novel mechanism of action. *J Am Coll Cardiol.* 2014;63(12\_S).
23. Farag M, Okafor O, Niespialowska-Steuden M, Spinhakis N, Artman B, Gorog D. Comparative effect of novel oral anticoagulants on global thrombotic status in patients with atrial fibrillation. *J Am Coll Cardiol.* 2015;65(10\_S).
24. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, et al. PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. *J Thromb Thrombolysis.* 2014;38(4):423-9.
25. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med.* 2011;365(8):699-708.
26. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J.* 2011;32(22):2781-9.
27. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med.* 2012;366(1):9-19.
28. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. *Stroke.* 2000;31(1):26-32.
29. Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. *Arterioscler Thromb Vasc Biol.* 2011;31(7):1689-95.
30. Erkol A, Oduncu V, Turan B, Kılıçgedik A, Sırma D, Gözübüyük G, et al. The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction. *J Thromb Thrombolysis.* 2014;38(3):339-47.
31. Kikkert WJ, Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, et al. D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. *J Thromb Thrombolysis.* 2014;37(2):155-64.
32. Hansen CH, Ritschel V, Halvorsen S, Andersen G, Bjørnerheim R, Eritsland J, et al. Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. *Thromb J.* 2015;13:31.
33. Sambola A, García Del Blanco B, Ruiz-Meana M, Francisco J, Barrabés JA, Figueras J, et al. Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy. *Thromb Haemost.* 2016;115(6):1129-37.
34. Zalewski J, Bogaert J, Sadowski M, Woznicka O, Doulaptsis K, Ntoumpanaki M, et al. Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction. *Thromb Haemost.* 2015;113(6):1258-69.
35. Denorme F, Wyseure T, Peeters M, Vandeputte N, Gils A, Deckmyn H, et al. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. *Stroke.* 2016;47(9):2419-22.

36. Benamer H, Tafflet M, Bataille S, Escolano S, Livarek B, Fourchard V, et al. Female gender is an independent predictor of in-hospital mortality after STEMI in the era of primary PCI: insights from the greater Paris area PCI Registry. *EuroIntervention*. 2011;6(9):1073-9.
37. Pancholy SB, Shantha GP, Patel T, Cheskin LJ. Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. *JAMA Intern Med*. 2014;174(11):1822-30.
38. van der Meer MG, Nathoe HM, van der Graaf Y, Doevendans PA, Appelman Y. Worse outcome in women with STEMI: a systematic review of prognostic studies. *Eur J Clin Invest*. 2015;45(2):226-35.
39. Gorog DA, Yamamoto J, Saraf S, Ishii H, Ijiri Y, Ikarugi H, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". *Int J Cardiol*. 2011;152(1):43-8.
40. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet*. 2013;382(9892):614-23.
41. Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. *JACC Cardiovasc Interv*. 2012;5(3):259-67.
42. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. *Nat Med*. 2009;15(6):665-73.
43. Jackson SP. The growing complexity of platelet aggregation. *Blood*. 2007;109(12):5087-95.
44. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. *J Am Coll Cardiol*. 2008;52(14):1128-33.
45. Aradi D, Vorobcsuk A, Lenkey Z, Horváth IG, Komócsi A. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. *Platelets*. 2010;21(1):1-10.
46. Brass L. Thrombus formation: stability matters. *Blood*. 2006;108:2883-4.

## Figure legends

### Figure 1: Distribution of Occlusion Time at 4 time-points

(A) Baseline, upon admission and before PPCI, (B) after administration of glycoprotein IIb/IIIa inhibitor (GPI), (C) at clinical stabilisation and just prior to hospital discharge, and (D) at 30-days post hospitalisation. OT=occlusion time. Y axis shows % patients.

### Figure 2: Distribution of Lysis Time at 4 time-points

(A) Baseline, upon admission and before PPCI, (B) after administration of glycoprotein IIb/IIIa inhibitor (GPI), (C) at clinical stabilisation and just prior to hospital discharge, and (D) at 30-days post hospitalisation. LT=occlusion time. Y axis shows % patients.

### Figure 3: Occlusion Time and Lysis Time (mean $\pm$ SD)

Occlusion time (OT) was prolonged after treatment with glycoprotein IIb/IIIa inhibitor (GPI)/unfractionated heparin (UFH) or after bivalirudin (Bival)/UFH, at discharge from hospital, and at 30 days post hospitalisation compared to baseline OT. Lysis time (LT) was shorter after GPI/UFH than at baseline. \* $p < 0.05$ , compared to baseline.

### Figure 4: MACE and major bleeding according to baseline Occlusion Time

Baseline OT in patients who did not have an adverse outcome is indicated by open bars; baseline OT in patients who had an adverse outcome is indicated by solid bars. \* $p < 0.05$ .

MI = myocardial infarction; CVA = cerebrovascular accident; CVD = cardiovascular death

### Figure 5: ROC curves for baseline Occlusion Time and Lysis Time

Receiver-operating characteristic (ROC) curves for (A) occlusion time (OT), and (B) lysis time (LT) at baseline. An  $LT \geq 3000s$  was identified as the optimal cut point to predict MACE outcome, with sensitivity of 31% and specificity of 89%.

**Figure 6: Probability of event-free survival according to baseline LT**

Kaplan-Meier curves showing probability of event-free survival (survival free of MACE) in STEMI patients based on the baseline LT. An  $LT \geq 3000s$  at baseline was associated with a hazard ratio of 3.31. Solid line indicates  $LT < 3000s$  and dotted line indicates  $LT \geq 3000s$ .

**Figure 7: Major adverse cardiovascular events and major bleeding according to baseline LT**

(A) Baseline LT in patients who did not have an outcome is indicated by open bars; baseline in patients who had an outcome is indicated by solid bars, (B) Baseline  $LT < 3000s$  is indicated by open bars; baseline  $LT \geq 3000s$  is indicated by solid bars. \* $p < 0.05$ . † $p = 0.05$ .

MI = myocardial infarction; CVA = cerebrovascular accident; CVD=cardiovascular death.

**Figure 8: HR for major adverse cardiovascular events according to baseline LT**

Hazard ratios (HR) for cardiovascular death (CVD), nonfatal myocardial infarction (MI), and stroke according to baseline lysis time (LT). The 95% confidence interval is shown in brackets. n: number of patients. \* $p < 0.05$ .

**Table 1: Exclusion Criteria**

Inability to consent
Current participation in another study
Less than 18 years of age
Known diagnosis of malignancy
Sepsis
Bleeding diathesis
Thrombolysis, warfarin, heparin, or GPI inhibitor treatment before sampling
Blood dyscrasia (platelets $<100 \times 10^9/L$ , haemoglobin $<80g/L$ , international normalized ratio $>1.4$ , activated partial thromboplastin time more than twice upper limit of normal, leukocyte count $<3.5 \times 10^9/L$ , neutrophil count $<1 \times 10^9/L$ )
Intolerance or contraindication to aspirin or clopidogrel
Complete follow-up over 1-year period not likely
Life expectancy $<12$ months due to known non-cardiovascular condition

**Table 2: Baseline Patient Characteristics**

	<b>Overall Group (n=82)</b>	<b>Baseline LT &lt;3000s (n=71)</b>	<b>Baseline LT ≥3000s (n=11)</b>	<b>p Value</b>
<b>Age, yrs</b>	63±12	63±12	64±10	0.444
<b>Male</b>	67 (81.7)	61 (85.9)	6 (54.5)	0.025
<b>Diabetes mellitus</b>	13 (15.9)	12 (16.9)	1 (9.1)	1.000
<b>Active smoker</b>	31 (37.8)	29 (40.8)	2 (18.2)	0.193
<b>Hypertension</b>	39 (47.6)	33 (46.5)	6 (54.5)	0.749
<b>Prior CAD</b>	12 (14.6)	10 (14.1)	2 (18.2)	0.660
<b>Renal insufficiency</b>	4 (4.9)	2 (2.8)	2 (18.2)	0.085
<b>PVD</b>	2 (2.4)	2 (2.8)	0	1.000
<b>Prior CVA</b>	1 (1.2)	1 (1.4)	0	1.000
<b>Prior aspirin use</b>	15 (18.3)	12 (16.9)	3 (27.3)	0.414
<b>Medications on discharge</b>				
<b>Aspirin</b>	80 (97.6)	70 (98.6)	10 (90.9)	0.252
<b>Clopidogrel</b>	79 (96.3)	69 (97.2)	10 (90.9)	0.355
<b>VKA</b>	4 (4.9)	4 (5.6)	0	1.000
<b>Beta-blocker</b>	64 (78.1)	56 (78.9)	8 (72.7)	0.699
<b>ACE inhibitor</b>	68 (82.9)	61 (85.9)	7 (63.6)	0.087
<b>Calcium antagonists</b>	12 (14.6)	9 (12.7)	3 (27.3)	0.199
<b>Statin</b>	69 (84.2)	61 (85.9)	8 (72.7)	0.369
<b>Nitrate</b>	9 (11.0)	8 (11.3)	1 (9.1)	1.000
<b>Insulin</b>	5 (6.1)	4 (5.6)	1 (9.1)	0.523
<b>Metformin</b>	5 (6.1)	5 (7.0)	0	1.000

Values are mean  $\pm$  standard deviation or n (%). Renal insufficiency was defined by creatinine levels  $>177 \mu\text{mol/L}$  (13). Prior aspirin use was defined as aspirin use before hospitalisation.

ACE: angiotensin-converting enzyme, CAD: coronary artery disease, CVA: cerebrovascular accident,

LT: lysis time, PVD: peripheral vascular disease, VKA: vitamin K antagonist.

**Table 3: Blood Tests on Admission**

	Overall Group (n=82)	Baseline LT <3000s (n=71)	Baseline LT ≥3000s (n=11)	p value
Haemoglobin (g/L)	139±20	140±19	130±27	0.115
Haematocrit (%)	42±6	42±6	39±6	0.077
Platelet count (x 10 <sup>9</sup> /L)	257±71	253±70	286±72	0.154
Creatinine (µmol/L)	94±39	91±29	117±76	0.039
C-reactive protein (mg/L)	13±20	13±18	17±30	0.571
Troponin T (ng/L), peak at 12 hrs	20,200±2770	21,300±2850	9,800±1670	0.336
Total Cholesterol (mmol/L)	4.8±1.2	4.8±1.2	4.9±1.2	0.711

Values are mean ± standard deviation.

Normal values: haemoglobin 130-180 g/L in adult males and 115-165 g/L in adult females; haematocrit 40-52 % in adult males and 36-47 % in adult females; platelet count 150-400 x10<sup>9</sup>/L; creatinine 60-110 µmol/L in adult males and 45-90 µmol/L in adult females; C-reactive protein 0-5 mg/L; troponin T <14 ng/L; total cholesterol ≤4.0 mmol/L.



**Table 4: Angiographic, Interventional, and Echocardiographic Patient Characteristics**

	<b>Overall Group (n=82)</b>	<b>Baseline LT &lt;3000s (n=71)</b>	<b>Baseline LT ≥3000s (n=11)</b>	<b>p value</b>
<b>1-vessel disease</b>	43 (52.4)	39 (54.9)	4 (36.4)	0.260
<b>2-vessel disease</b>	22 (26.8)	17 (23.9)	5 (45.5)	0.141
<b>3-vessel disease</b>	16 (19.5)	14 (19.7)	2 (18.2)	0.902
<b>Culprit vessel</b>				
<b>LAD</b>	25 (30.9)	24 (33.8)	1 (9.1)	0.131
<b>Diagonal</b>	2 (2.5)	2 (2.8)	0	0.901
<b>LCA</b>	9 (11.1)	6 (8.5)	3 (27.3)	0.080
<b>OM</b>	3 (3.7)	3 (4.2)	0	0.923
<b>RCA</b>	42 (51.9)	35 (49.3)	7 (63.6)	0.381
<b>GPI use</b>	58 (70.7)	52 (73.2)	6 (54.5)	0.285
<b>Bivalirudin use</b>	4 (4.9)	3 (4.2)	1 (9.1)	0.444
<b>Balloon predilatation</b>	57 (69.5)	49 (69.0)	8 (72.7)	1.000
<b>Stent implantation</b>				
<b>BMS</b>	19 (24.4)	15 (21.1)	4 (36.4)	0.273
<b>DES</b>	59 (75.6)	52 (73.2)	7 (63.6)	0.514
<b>TIMI-3 flow</b>				
<b>Before PCI</b>	14 (17.5)	13 (18.3)	1 (9.1)	0.461
<b>After PCI</b>	69 (86.3)	59 (83.1)	10 (90.9)	0.520
<b>LV function after index event</b>				
<b>Normal (EF ≥ 55%)</b>	45 (59.2)	37 (52.1)	8 (72.7)	0.212
<b>Mildly impaired (EF 45-54%)</b>	17 (22.4)	16 (22.5)	1 (9.1)	0.333

<b>Moderately impaired (EF 36-44%)</b>	13 (17.1)	13 (18.3)	0	0.264
<b>Severely impaired (EF ≤ 35%)</b>	1 (1.3)	1 (1.4)	0	0.673
<b>Door to balloon time, min</b>	24±16	23±16	26±14	0.519
<b>Call to balloon time, min</b>	100±18	100±19	98±14	0.940

---

Values are n (%).

BMS: bare metal stent, DES: drug eluting stent, EF: ejection fraction, GPI: glycoprotein IIb/IIIa inhibitor, LAD: left anterior descending coronary artery, LCA: left circumflex coronary artery, LT: lysis time, LV: left ventricular, OM: obtuse marginal coronary artery, PCI: percutaneous coronary intervention, RCA: right coronary artery, TIMI: Thrombolysis in Myocardial Infarction.

**Table 5: Clinical outcome at 12 months' follow-up**

	Overall Group (n=82)	Baseline LT <3000 s (n=71)	Baseline LT ≥3000 s (n=11)	HR (95% CI)	p value
<b>Cardiovascular death, nonfatal MI, and stroke</b>	13 (15.9)	9 (12.7)	4 (36.4)	3.31 (1.02-10.78)	0.047
<b>Cardiovascular death*</b>	8 (9.8)	5 (7.0)	3 (27.3)	4.18 (0.99-17.51)	0.05
<b>Nonfatal MI</b>	3 (3.7)	2 (2.8)	1 (9.1)	3.96 (0.36-43.94)	0.263
<b>Stroke**</b>	2 (2.4)	2 (2.8)	0	NA	NA
<b>Major bleeding</b>	2 (2.4)	1 (1.4)	1 (9.1)	8.79 (0.55-140.46)	0.124


Values are n (%).

CI: confidence interval, HR: hazard ratio, LT: lysis time, MI: myocardial infarction, NA: not applicable.


\* Cardiovascular deaths defined as death in the presence of acute coronary syndrome, significant cardiac arrhythmia, or refractory congestive heart failure, or death attributed to cardiovascular cause at post-mortem.

\*\* Causes of stroke were ischaemic stroke.


**(A)**




**(B)**




**(C)**




**(D)**




**(A)**




**(B)**




**(C)**




**(D)**




(A)




(B)







(A)




(B)







(A)



(B)

